Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | GSK3A | P49840 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5012592 | 1.00 | LMNA (0.52) | LMNAPIM1GSK3AGSK3BPIM3 | |
| SCHEMBL20528735 | 0.76 | LMNA (0.50) | LMNAPIM1GSK3AGSK3BPIM3 | |
| Levonadifloxacin SCHEMBL36594 | 0.69 | LMNA (1.00) | LMNA | |
| Nadifloxacin SCHEMBL36593 | 0.69 | LMNA (1.00) | LMNA | |
| Nadifloxacin SCHEMBL3818938 | 0.69 | LMNA (1.00) | LMNA | |
| Levonadifloxacin SCHEMBL3973065 | 0.68 | LMNA (0.98) | LMNA | |
| Levonadifloxacin SCHEMBL3972618 | 0.68 | LMNA (0.98) | LMNA | |
| SCHEMBL4638291 | 0.67 | LMNA (0.78) | LMNA | |
| SCHEMBL3890878 | 0.67 | LMNA (0.78) | LMNA | |
| SCHEMBL16518627 | 0.67 | LMNA (0.85) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918289-A2 | Crystalline fluoroquinolone arginine salt form | Wockhardt Limited (IN) | 2008-05-07 | — | — | EP | claimed |
| US-20040063948-A1 | Crystalline fluoroquinolone arginine salt form | WOCKHARDT LIMITED | 2004-04-01 | — | — | US | claimed |
| US-20030225119-A1 | CRYSTALLINE FLUOROQUINOLONE ARGININE SALT FORM | WOCKHARDT LIMITED | 2003-12-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225119-A1 | CRYSTALLINE FLUOROQUINOLONE ARGININE SALT FORM | ARG1, ARGLU1, Q6ZSR9 | LMNA 3548/4885PIM1 1944/4885GSK3A 3800/4885 |
| US-20040063948-A1 | Crystalline fluoroquinolone arginine salt form | ARG1, ARGLU1, Q6ZSR9 | LMNA 3548/4885PIM1 1944/4885GSK3A 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.